Skip to main content

Table 2 Total adverse events reported per cancer

From: Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer

Disease Number of Patients Taken off therapy secondary to toxicity Death secondary to toxicity Elevation AST any grade Elevation AST grade 3–4 Elevation ALT any grade Elevation ALT grade 3–4 Diarrhea any grade Diarrhea grade 3–4
HCC 314 16 0 51 30 41 16 40 4
NSCLC 1866 75 10 43 6 47 5 161 22
Melanoma 4118 548 21 156 33 179 38 1242 320
  1. HCC Hepatocellular Carcinoma, NSCLC Non-small cell lung cancer, AST aspartate aminotransferase, ALT alanine aminotransferase